SYNCOM FORMU (I) LTD
Latest filings
- Quarterly compliance certificate for dematerialization of securities · Compliance
- Final dividend of Rs 0.10 per share approved by Syncom Formulations · Corporate Actions
- Syncom Formulations: MD appointed, family board changes confirmed at AGM · Management Changes
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures and sells pharmaceutical drugs and formulations, which generated 99.1% of segment revenue (Rs. 512.74 crore) in FY26, with a segment EBIT of Rs. 98.66 crore. A small renting-of-property line contributed 0.7% of segment revenue (Rs. 3.70 crore, EBIT Rs. 3.00 crore), and commodity trading contributed 0.2% (Rs. 1.10 crore, near-breakeven). For FY26, consolidated revenue from operations stood at Rs. 489.17 crore with a net profit of Rs. 76.44 crore and EBITDA margin of 22.2%. The cost structure is dominated by materials at 45.2% of revenue, followed by employee cost at 13.7%, other operating expenses at 12.3%, depreciation at 1.3%, and capex at 2.4% of revenue. The company reported a sharp YoY profit jump in FY26, with PAT rising roughly 55% on consolidated basis, even as Q3 FY26 revenue dipped about 9.8% YoY. During FY26, the company purchased the entire 7th floor of Trade Star building on Andheri-Kurla Road, Mumbai, from HDFC Bank for Rs. 57.26 crore, and is contesting a Rs. 1.41 crore GST demand notice.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
SYNCOMF · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from SYNCOM FORMU (I) LTD's filed financials and exchange disclosures
What does SYNCOM FORMU (I) LTD do?
SYNCOM FORMU (I) LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol SYNCOMF.
Is SYNCOM FORMU (I) LTD profitable?
Yes. Over the trailing twelve months SYNCOM FORMU (I) LTD reported a net profit of ₹86 Cr on revenue of ₹498 Cr.
Does SYNCOM FORMU (I) LTD pay a dividend?
Not in the latest reported year — SYNCOM FORMU (I) LTD's dividend payout for FY26 was nil.
Is SYNCOM FORMU (I) LTD debt-free?
On a net basis, yes. It reported borrowings of ₹1.47 Cr on its 31 Mar 2026 balance sheet, but holds ₹3.67 Cr more cash than debt.
Is SYNCOM FORMU (I) LTD expensive compared with its peers?
On trailing P/E, SYNCOM FORMU (I) LTD ranks 59 of 158 in Pharmaceuticals — cheaper than 63% of them, against an industry median of 30.1×. This is a position, not a valuation judgement.
How much does the SYNCOM FORMU (I) LTD share price move in a day?
On a typical session SYNCOM FORMU (I) LTD moves 1.47% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
Where can I track SYNCOM FORMU (I) LTD's announcements?
Every NSE and BSE filing by SYNCOM FORMU (I) LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.